We are live on ! Find out more
TTNP

Titan Pharmaceuticals

Delisted

TTNP was delisted on the 1st of October, 2025.

35 hedge funds and large institutions have $5.47M invested in Titan Pharmaceuticals in 2017 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 5 increasing their positions, 8 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0%0% (-0%)

13% less funds holding

Funds holding: 4035 (-5)

31% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 16

38% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 8

50% less capital invested

Capital invested by funds: $10.9M → $5.47M (-$5.41M)

Holders
35
Holders Change
-5
Holders Change %
-12.5%
% of All Funds
0.87%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
11
Increased
5
Reduced
8
Closed
16
Calls
$190K
Puts
Net Calls
+$190K
Net Calls Change
-$543K
Name Holding Trade Value Shares
Change
Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$1.26M -$112K -12 -6%
MERSOM
2
Municipal Employees' Retirement System of Michigan
Michigan
$576K +$782K +84 New
Renaissance Technologies
3
Renaissance Technologies
New York
$530K +$102K +11 +17%
State Street
4
State Street
Massachusetts
$467K -$121K -13 -16%
Millennium Management
5
Millennium Management
New York
$437K +$595K +64 New
WPA
6
Winning Points Advisors
Florida
$289K +$381K +41 New
Goldman Sachs
7
Goldman Sachs
New York
$195K
Geode Capital Management
8
Geode Capital Management
Massachusetts
$165K -$93K -10 -29%
ECM
9
Element Capital Management
New York
$156K +$214K +23 New
PP
10
Paloma Partners
Connecticut
$136K +$186K +20 New
Jacobs Levy Equity Management
11
Jacobs Levy Equity Management
New Jersey
$130K +$177K +19 New
BlackRock
12
BlackRock
New York
$123K -$1.91M -205 -92%
Dimensional Fund Advisors
13
Dimensional Fund Advisors
Texas
$113K
LP
14
LMR Partners
United Kingdom
$105K +$140K +15 New
Deutsche Bank
15
Deutsche Bank
Germany
$103K +$83.7K +9 +150%
Northern Trust
16
Northern Trust
Illinois
$92K -$409K -44 -77%
D.E. Shaw & Co
17
D.E. Shaw & Co
New York
$84K +$46.5K +5 +71%
Bank of America
18
Bank of America
North Carolina
$82K
Morgan Stanley
19
Morgan Stanley
New York
$67K -$83.7K -9 -47%
Legal & General Group
20
Legal & General Group
United Kingdom
$60K +$74.4K +8 +800%
California Public Employees Retirement System
21
California Public Employees Retirement System
California
$53K
Susquehanna International Group
22
Susquehanna International Group
Pennsylvania
$52K +$74.4K +8 New
Barclays
23
Barclays
United Kingdom
$47K +$46.5K +5 +250%
OAM
24
Oxford Asset Management
United Kingdom
$27K +$37.2K +4 New
Bank of New York Mellon
25
Bank of New York Mellon
New York
$24K -$121K -13 -76%

TTNP Hedge Fund Activity: Q2 2017 in Review

35 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q2 2017, worth a combined $5.47M — down 50% from $10.9M a quarter earlier.

Sellers outnumbered buyers: 16 funds closed out of TTNP and 11 opened new positions — a net loss of 5 holders — while 8 trimmed existing stakes and 5 added.

The largest buyer was Municipal Employees' Retirement System of Michigan, opening a new position worth an estimated $782K. The largest seller was BlackRock, cutting an estimated $1.91M.

  • 35 institutional investors held Titan Pharmaceuticals (TTNP) as of Q2 2017, down from 40 in Q1 2017.
  • Funds reported $5.47M of Titan Pharmaceuticals stock for Q2 2017, down 50% quarter-over-quarter.
  • 11 funds opened new Titan Pharmaceuticals positions in Q2 2017 and 16 closed out, a net change of -5 holders.
  • The largest Titan Pharmaceuticals buyer in Q2 2017 was Municipal Employees' Retirement System of Michigan, an estimated $782K added.
  • The largest Titan Pharmaceuticals seller in Q2 2017 was BlackRock, an estimated $1.91M sold.

Based on aggregated 13F filings for Q2 2017.